NCT07154238View on ClinicalTrials.gov

Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.

Not yet recruitingOBSERVATIONAL
Enrollment

2,546

Participants

Timeline

Start Date

August 27, 2025

Primary Completion Date

August 30, 2026

Study Completion Date

August 30, 2026

Conditions
Obesity
Interventions
OTHER

No treatment given

No treatment given

Trial Locations (1)

32545

Novo Nordisk Investigational Site, Bad Oeynhausen

Sponsors

Lead Sponsor

Novo Nordisk A/S
All Listed Sponsors
lead

Novo Nordisk A/S

INDUSTRY

NCT07154238 - Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study. | Biotech Hunter | Biotech Hunter